中文摘要：

湿性年龄相关性黄斑变性（age—relatedmaculardegeneration，AMD）是老年人群视力丧失的主要原因之一，目前其发病原因尚不明确。研究已证实血管内皮生长因子与湿性AMD有明确相关性，已有多种抗血管内皮生长因子的药物应用于其治疗。玻璃体腔注射雷珠单抗能抑制血管内皮生长因子，阻断新生血管生长及渗漏而发挥治疗作用，其在湿性AMD的治疗中已显示出确切疗效。本文对雷珠单抗治疗湿性AMD的进展作一综述，包括雷珠单抗治疗湿性AMD的方案及疗效，影响其疗效的因素，联合治疗，以及雷珠单抗治疗湿性AMD的不良反应等几个方面。 ，

英文摘要：

Wet age-related macular degeneration （AMD） is one of the main causes of vision loss in elderly people, and its etiology is not clear. In terms of pathogenesis, it has been confirmed that vascular en- dothelial growth factor and wet AMD have a clear correlation. Therefore, there are many kinds of anti-vascu- lar endothelial growth factor drugs used in the disease. Intravitreal Ranibizumab can inhibit vascular endo- thelial growth factor and block the growth and leakage of new blood vessels to play a role. The Ranibizumab has been shown to be a definite therapeutic effect in the treatment of wet AMD. The progress of Ranibizumab in the treatment of wet AMD is reviewed in this article, including the treatment efficacy, the factors of affect- ing the efficacy, the combined therapy, and the adverse reaction and so on.